Seray Saray, Hüseyin Kanmaz
Eurasian Journal of Medical Investigation - 2025;9(3):113-119
This study aimed to elucidate the prognostic significance of biomarkers indicative of inflammation, including the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), and hemoglobin, albumin, lymphocyte, and platelet (HALP) scores, prior to treatment with CDK4/6 inhibitors in patients with hormone receptor-positive (HoR+)/HER2-negative (HER2-) advanced breast cancer. A total of 38 patients with HR+/HER2- metastatic breast cancer were included. The median age was 59.5 years, and 78.9% were postmenopausal. Disease progression occurred in 55.2% of patients, and 7.8% died during follow-up. ROC analysis identified optimal prognostic cut-off values for PLR (128; AUC = 0.786, p=0.003) and HALP (32.6; AUC = 0.875, p=0.001), while NLR and CAR were not significant predictors. Median overall survival (OS) was 45 months, which was shorter in pre/perimenopausal patients and those with visceral metastases or elevated CAR (>= 0.75). Multivariate analysis confirmed menopausal status, visceral metastasis, and high CAR as independent prognostic factors for OS. The CAR index is a reliable, straightforward, readily accessible, and cost-efficient tool for predicting the prognosis of patients with metastasis.
